The final decision was not reached on the first attempt. The path to getting 'Camzyos,' the first novel drug for obstructive hypertrophic cardiomyopathy (oHCM), listed for reimbursement seems to be challenging.

According to the industry sources, BMS Korea’s Camzyos (mavacamten), a novel drug used to treat obstructive hypertrophic cardiomyopathy (oHCM), was considered for review by the Drug Reimbursement Evaluation Committee (DREC) of Health Insurance Review and Assessment Service (HIRA) but received a 'reconsideration' decision.

After clearing the Economic Evaluation Committee of Health Insurance Review, it was rapidly considered for the DREC review. However, as the drug is the first-i